Replies to post #205316 on Biotech Values

[DewDiligence]

BMY—a lot is riding on the yervoy plus opdivo combo in NSCLC.

True; however, BMY has several backup plans for Opdivo in NSCLC.

[DewDiligence]

BMY won't pursue FDA accelerated approval for Opdivo/Yervoy combination in first-line NSCLC:

http://finance.yahoo.com/news/bristol-myers-squibb-provides-regulatory-233000138.html

No further information is being disclosed to maintain the integrity of ongoing Opdivo/Yervoy phase-3 trials in this setting.

BMY is -6% in AH trading on this news.